Izawa Mizuki, Kosaka Takeo, Nakamura Kohei, Oba Junna, Hishida Tomoyuki, Hongo Hiroshi, Mikami Shuji, Nishihara Hiroshi, Oya Mototsugu
Department of Urology Keio University School of Medicine Tokyo Japan.
Genomics Unit Keio Cancer Center Keio University School of Medicine Tokyo Japan.
IJU Case Rep. 2020 Oct 15;4(1):14-17. doi: 10.1002/iju5.12224. eCollection 2021 Jan.
Most metastatic prostate cancers acquire the capacity for androgen-independent growth and become resistant to androgen deprivation therapy. A patient-focused treatment strategy is needed for aggressive castration-resistant prostate cancer.
We report the case of a 62-year-old man who presented with prostatic adenocarcinoma who was treated by radiation and combined androgen blockade. After completion of first-line therapy, he was diagnosed with multiple metastatic castration-resistant prostate cancer in the lung. Second-line therapy with abiraterone acetate resulted in partial remission of the lung metastases. Thoracic surgery was performed to remove the single lung metastasis remaining. Next-generation sequencing of the specimens demonstrated homozygous loss of . We note in this case a heterogeneous response to abiraterone acetate may be related to the somatic deletions.
We present the first Japanese case of a metastatic abiraterone acetate-resistant castration-resistant prostate cancer accompanied by BRCA2 mutation.
大多数转移性前列腺癌获得雄激素非依赖性生长能力，并对雄激素剥夺疗法产生抗性。侵袭性去势抵抗性前列腺癌需要以患者为中心的治疗策略。
我们报告了一名62岁患有前列腺腺癌的男性病例，该患者接受了放疗和联合雄激素阻断治疗。一线治疗完成后，他被诊断为肺部多发转移性去势抵抗性前列腺癌。醋酸阿比特龙二线治疗使肺转移灶部分缓解。随后进行了胸外科手术以切除残留的单个肺转移灶。对标本进行的二代测序显示……纯合缺失。我们注意到在该病例中，对醋酸阿比特龙的异质性反应可能与体细胞……缺失有关。
我们报告了日本首例伴有BRCA2突变的转移性醋酸阿比特龙抵抗性去势抵抗性前列腺癌病例。
